Paragon Care Ltd (PGC) - Total Assets
Based on the latest financial reports, Paragon Care Ltd (PGC) holds total assets worth AU$1.31 Billion AUD (≈ $923.81 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PGC net asset value for net asset value and shareholders' equity analysis.
Paragon Care Ltd - Total Assets Trend (1999–2025)
This chart illustrates how Paragon Care Ltd's total assets have evolved over time, based on quarterly financial data.
Paragon Care Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Paragon Care Ltd's total assets of AU$1.31 Billion consist of 61.6% current assets and 38.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 1.8% |
| Accounts Receivable | AU$402.71 Million | 32.6% |
| Inventory | AU$282.54 Million | 22.9% |
| Property, Plant & Equipment | AU$75.82 Million | 6.1% |
| Intangible Assets | AU$384.64 Million | 31.2% |
| Goodwill | AU$264.85 Million | 21.5% |
Asset Composition Trend (1999–2025)
This chart illustrates how Paragon Care Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Paragon Care Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Paragon Care Ltd's current assets represent 61.6% of total assets in 2025, a decrease from 100.0% in 1999.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2025, down from 98.7% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 32.6% of total assets.
Paragon Care Ltd Competitors by Total Assets
Key competitors of Paragon Care Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$7.84 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$55.91 Million |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥233.15 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥83.17 Billion |
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥112.28 Billion |
Paragon Care Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.94 | 1.02 | 1.40 |
| Quick Ratio | 0.58 | 0.62 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-53.45 Million | AU$16.33 Million | AU$28.48 Million |
Paragon Care Ltd - Advanced Valuation Insights
This section examines the relationship between Paragon Care Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 9.1% |
| Total Assets | AU$1.23 Billion |
| Market Capitalization | $181.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Paragon Care Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Paragon Care Ltd's assets grew by 9.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Paragon Care Ltd (1999–2025)
The table below shows the annual total assets of Paragon Care Ltd from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.23 Billion ≈ $873.17 Million |
+9.12% |
| 2024-06-30 | AU$1.13 Billion ≈ $800.18 Million |
+152.14% |
| 2023-06-30 | AU$448.52 Million ≈ $317.36 Million |
+2.30% |
| 2022-06-30 | AU$438.44 Million ≈ $310.22 Million |
+50.19% |
| 2021-06-30 | AU$291.92 Million ≈ $206.55 Million |
-0.09% |
| 2020-06-30 | AU$292.17 Million ≈ $206.73 Million |
-23.95% |
| 2019-06-30 | AU$384.20 Million ≈ $271.84 Million |
+9.85% |
| 2018-06-30 | AU$349.75 Million ≈ $247.47 Million |
+110.62% |
| 2017-06-30 | AU$166.05 Million ≈ $117.49 Million |
+12.36% |
| 2016-06-30 | AU$147.79 Million ≈ $104.57 Million |
+264.14% |
| 2015-06-30 | AU$40.59 Million ≈ $28.72 Million |
+50.59% |
| 2014-06-30 | AU$26.95 Million ≈ $19.07 Million |
+46.56% |
| 2013-06-30 | AU$18.39 Million ≈ $13.01 Million |
+11.37% |
| 2012-06-30 | AU$16.51 Million ≈ $11.68 Million |
-8.55% |
| 2011-06-30 | AU$18.05 Million ≈ $12.77 Million |
+53.04% |
| 2010-06-30 | AU$11.80 Million ≈ $8.35 Million |
+198.03% |
| 2009-06-30 | AU$3.96 Million ≈ $2.80 Million |
+194.59% |
| 2008-06-30 | AU$1.34 Million ≈ $950.81K |
-7.98% |
| 2007-06-30 | AU$1.46 Million ≈ $1.03 Million |
-45.72% |
| 2006-06-30 | AU$2.69 Million ≈ $1.90 Million |
+11.91% |
| 2005-06-30 | AU$2.40 Million ≈ $1.70 Million |
+227.90% |
| 2004-06-30 | AU$733.20K ≈ $518.78K |
+99.06% |
| 2003-06-30 | AU$368.33K ≈ $260.62K |
-96.11% |
| 2002-06-30 | AU$9.46 Million ≈ $6.69 Million |
-10.70% |
| 2001-06-30 | AU$10.59 Million ≈ $7.50 Million |
+69.18% |
| 2000-06-30 | AU$6.26 Million ≈ $4.43 Million |
-6.41% |
| 1999-06-30 | AU$6.69 Million ≈ $4.73 Million |
-- |
About Paragon Care Ltd
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more